Patient P-02584
Synthetic patientMETA-24 · Day 100 · 35–44 · F · baseline S09Steering view · 3DOpen companion preview
Therapy response
Favorable
Tolerance
Improving
GI state
Favorable
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
12%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S09
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Toxicity-18
- Inflammatory activity-11
- Nutritional resilience+9
- Treatment adherence-5
- GI instability+4
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable49 min
stable · -0.7 vs previous 14 d
Sleep duration
Wearable7.1 h
stable · -0.1 vs previous 14 d
Energy level
Daily log7.5/10
stable · -0.1 vs previous 14 d
Steps
Wearable4,579
stable · +122 vs previous 14 d
GI burden
Companion14.4/100
worsening · +5.3 vs previous 14 d
Adherence
Companion86.8 %
worsening · -3.9 vs previous 14 d
Sleep quality
Wearable56.2/100
stable · -1.5 vs previous 14 d
Glucose, CGM daily mean
CGM134 mg/dL
stable · +2.2 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 92 from the failing basin, 10 from restoration.
Good elements to keep
- Protein (supports)perturbation · steering +10.9
- Butyrate producers intacthidden · steering +7.5
- Proteinsupporter · GI -5.7 next day
Main detractors to watch
- IL6 high-expression varianthidden · steering -7.3
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-5.7supporter · 95%
- Dietary fat load+1.8no signal · 42%
- Ultra-processed food+1.6no signal · 43%
- Caffeine-1no signal · 23%
- Alcohol-0.6no signal · 15%
- Histamine load+0.5no signal · 15%
- Simple carbohydrates-0.3no signal · 15%
- Insoluble fibre+0.3no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 3.4 · butyrate capacity 65/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 64 ms
- Sleep
- 7.4 h
- Steps
- 4,036
- Resting HR
- 66 bpm
Daily log: GI score 14, nutritional resilience 74, adherence 87.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02555 | 46% | S01 | AD-05 | no change | 79 |
| P-02277 | 39% | S05 | AD-05 | improved | 92 |
| P-02282 | 39% | S01 | BR-03 | no change | 88 |
| P-02013 | 33% | S14 | BR-03 | no change | 94 |
| P-02280 | 32% | S07 | BR-03 | no change | 50 |
| P-02193 | 32% | S11 | CR-01 | improved | 87 |
| P-02565 | 54% | S09 | DT-01 | no change | 79 |
| P-02081 | 36% | S20 | DT-01 | no change | 88 |
| P-02337 | 36% | S18 | DT-01 | no change | 100 |
| P-02249 | 34% | S09 | DT-01 | improved | 100 |
| P-02218 | 33% | S01 | DT-01 | improved | 61 |
| P-02462 | 33% | S12 | DT-01 | improved | 65 |